Cargando…

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT

Detalles Bibliográficos
Autores principales:	Bohl, S, von Harsdorf, S, Mulaw, M, Hofmann, S, Babiak, A, Maier, C P, Schnell, J, Hütter-Krönke, L-M, Scholl, K, Wais, V, Schlenk, R F, Bullinger, L, Ringhoffer, M, Döhner, H, Bunjes, D, Bommer, M, Kuchenbauer, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935978/ https://www.ncbi.nlm.nih.gov/pubmed/26950380 http://dx.doi.org/10.1038/bmt.2016.4

Ejemplares similares

FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
por: Owattanapanich, Weerapat, et al.
Publicado: (2019)

P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS
por: Ussmann, J., et al.
Publicado: (2022)

Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report
por: Wang, Jin, et al.
Publicado: (2014)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation
por: Hütter-Krönke, Marie Luise, et al.
Publicado: (2023)

Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients
por: Greiner, Jochen, et al.
Publicado: (2019)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Risk Factors Influencing Humoral Response to COVID 19 Vaccination after Allogeneic Stem Cell Transplantation
por: Hütter-Krönke, Marie Luise, et al.
Publicado: (2022)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Bilateral Conjunctival Infiltration as an Extramedullary Relapse of AML
por: Mozaheb, Zahra, et al.
Publicado: (2018)

The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice
por: Meri, Seppo, et al.
Publicado: (2022)

COVID-19 Vaccination after Allogeneic Stem Cell Transplantation: Real Word Data on Safety and Efficacy. a Single Center Experience.
por: Neagoie, Adela, et al.
Publicado: (2021)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
por: Rouhi, Arefeh, et al.
Publicado: (2016)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
por: Agrawal, Mridul, et al.
Publicado: (2019)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Fulminant isolated adenovirus hepatitis 5 months after haplo-identical HSCT for AML
por: Detrait, Marie, et al.
Publicado: (2015)

Nilotinib hampers the proliferation and function of CD8(+) T lymphocytes through inhibition of T cell receptor signalling
por: Chen, J, et al.
Publicado: (2008)

Increasing Role of Targeted Immunotherapies in the Treatment of AML
por: Greiner, Jochen, et al.
Publicado: (2022)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
por: Wang, Luxiang, et al.
Publicado: (2023)

Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study
por: Caballero-Velázquez, Teresa, et al.
Publicado: (2023)

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
por: Noviello, Maddalena, et al.
Publicado: (2019)

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
por: Thiel, V N, et al.
Publicado: (2017)

P478: MOLECULAR CHARACTERIZATION OF EXTRAMEDULLARY LOCALIZATIONS IN ACUTE MYELOID LEUKEMIA (AML)
por: Silvestrini, Giorgia, et al.
Publicado: (2023)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia
por: Krowiorz, K, et al.
Publicado: (2016)

Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis
por: Braitsch, Krischan, et al.
Publicado: (2022)

Granulocytic Sarcoma of the Uterus: A Rare Presentation of Extramedullary Relapse of AML and Importance of MRI
por: Ucar, Murat, et al.
Publicado: (2014)

Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT
por: Machuldova, Alena, et al.
Publicado: (2021)

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)
por: Pohlmann, Alexander, et al.
Publicado: (2023)

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
por: Heidel, Florian H., et al.
Publicado: (2013)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

Dentistry consensus on HSCT – Part III: Special topics – Dentistry on HSCT
por: Santos, Paulo Sérgio da Silva, et al.
Publicado: (2023)

Dental consensus on HSCT – Part II: dental Care during HSCT
por: Gobbi, Marcella Ferreira, et al.
Publicado: (2023)

Establishing the hematopoietic stem cell transplant (HSCT) in a developing country; the journey of HSCT in Semarang, Indonesia
por: Santosa, Damai, et al.
Publicado: (2020)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers
por: Lueck, Sonja C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gmt75ps5dk0h0jh4n19g0nundf